Phase 2,3 trial data of India’s first mRNA COVID vaccine handed over to DCGI: Report

The company has also developed a omicron-specific vaccine Which will be tested on humans for efficacy and immunogenicity.

Earlier, Director General of the Indian Council of Medical Research (ICMR), Dr Balram Bhargava said that this vaccine is going to be useful in the treatment of other diseases in future and India is moving towards becoming a vaccine superpower.

“India is moving towards becoming a Vaccination The superpower and the fact that these vaccines are going to be available for other diseases,” Dr Bhargava said.

Dr VK Paul, Member (Health), NITI Aayog on the importance of mRNA vaccine had said, “This mRNA platform of vaccine is an asset in the wake of COVID today and goes beyond that for other diseases too. Be it malaria, dengue or TB. There are many diseases for which we are still looking for cheap and effective vaccines.”

Genoa Biopharmaceuticals has presented Phase-II and Phase-III data for the mRNA vaccine. Recommendations regarding vaccines will come only after evaluation by the Subject Expert Committee (SEC).

Meanwhile, India started immunizing children aged 12 to 14 as it expands its COVID-19 vaccination coverage on March 16.

Children in the above age group are given the Corbevax vaccine manufactured by Hyderabad-based Biological E. It is India’s first indigenously developed Receptor Binding Domain (RBD) protein sub-unit vaccine against COVID-19.

Additionally, all people above 60 years of age are now eligible for the precautionary dose, as the comorbidity condition has been removed for this age group. The precautionary dose (same as the previous two doses) is to be administered no later than 9 months (36 weeks) after the date of the second vaccination.

This story has been published without modification in text from a wire agency feed. Only the title has been changed.